Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elite's Opioid Carries Risk Of Overdose After Heavy Meal, FDA Says

Executive Summary

Complete response letter explains that SequestOx labeling could not adequately mitigate the risk; firm to propose another bioequivalence study in patients receiving drug after eating fatty food.

Advertisement

Related Content

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
Abuse-Deterrent Opioids Forcing FDA To Better Define 'Food'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel